PEUdR

Drug Profile

PEUdR

Latest Information Update: 15 Mar 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Center (Tokyo); Taiho Pharmaceutical; Teikyo University
  • Class Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleoside transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 15 Mar 2007 Discontinued - Preclinical for Solid tumours in Japan (unspecified route)
  • 20 Jun 2001 No-Development-Reported for Solid tumours in Japan (Unknown route)
  • 10 Jul 1996 Preclinical development for Solid tumours in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top